• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Where Dr Victoria Villaflor Thinks the Future of Precision Medicine Is Headed

Video

There are small subgroups within each tumor type and within each molecular type, and someday, we might be able to actually pair the 2 to give patients a little bit more personalization and precision to their treatments, said Victoria Villaflor, MD, associate professor of Medicine, hematology and oncology.

There are small subgroups within each tumor type and within each molecular type, and someday, we might be able to actually pair the 2 to give patients a little bit more personalization and precision to their treatments, said Victoria Villaflor, MD, associate professor of Medicine, hematology and oncology.

Transcript

Looking ahead, where do you think the future of precision medicine is headed?

Where I think and where I hope, I hope collide. What I think at some point in the future is that patients are going to go in and have testing done and be evaluated. And based on a number of items, including their performance status, other underlying comorbidities, and probably a chip of all of their genetic and molecular material, is going to actually be put into a computer, which will hopefully spit out "this will be the best treatment or intervention," because it’s not all based on treatment, but also on interventions for you, whether it be surgery, radiation, some kind chemotherapy, or a targeted therapy, or immune therapy.

That being said, there’s a lot of other things that will play a role, and they will need to obviously be monitored. It won’t be like walking and hitting the computer key like you do in a grocery store. But, I think that things are going to advance based on a lot of the smaller data because not all people are alike the way we used to do studies. There are small subgroups within each tumor type and within each molecular type, and hopefully, at some day, we’ll be able to actually pair the 2 to give patients a little bit more personalization and precision to their treatments.

Related Videos
Screenshot of Stephen Freedland, MD, during a video interview
Phaedra Corso, PhD, associate vice president for research at Indiana University
William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Screenshot of Angela Jia, MD, PhD, during a video interview
Nancy Dreyer, MPH, PhD, FISE, chief scientific advisor to Picnic Health
Screenshot of Alexander Kutikov, MD, during a video interview
Neil Goldfarb, CEO, Greater Philadelphia Business Coalition on Health
Screenshot of Mary Dunn, MSN, NP-C, OCN, RN, during a video interview
Seth Berkowitz, MD, MPH, associate professor of medicine, University of North Carolina at Chapel Hill
Inma Hernandez, PharmD, PhD, professor at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.